First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study found technetium-99m-labeled fucoidan (99mTc-fucoidan) is safe and shows good biodistribution for imaging P-selectin. However, its effectiveness for deep vein thrombosis (DVT) imaging was not supported by in vivo results.
Area Of Science
- Nuclear medicine
- Molecular imaging
- Biochemistry
Background
- P-selectin is upregulated in atherothrombosis, making it a target for molecular imaging.
- Fucoidan, a polysaccharide from brown algae, has high affinity for P-selectin.
- Early detection of thrombosis can be improved with targeted molecular imaging agents.
Purpose Of The Study
- To evaluate the safety, biodistribution, and dosimetry of 99mTc-fucoidan in healthy volunteers.
- To assess the binding of 99mTc-fucoidan to human thrombi ex vivo and in vivo.
- To investigate 99mTc-fucoidan as a potential imaging agent for deep vein thrombosis (DVT).
Main Methods
- Ten healthy volunteers received intravenous 99mTc-fucoidan for whole-body scans up to 24 hours.
- Gamma counting measured 99mTc-fucoidan uptake in 11 ex vivo human thrombi.
- SPECT/CT imaging was performed on three patients with newly diagnosed DVT.
Main Results
- 99mTc-fucoidan was well-tolerated with no adverse events and favorable dosimetry.
- Ex vivo thrombi showed tracer binding, reduced by 16% with Sialyl Lewis X.
- In vivo imaging demonstrated specific uptake at the thrombus site in only one of three DVT patients.
Conclusions
- 99mTc-fucoidan demonstrates a favorable safety profile and biodistribution.
- Specific binding to human thrombi was observed in both ex vivo and in vivo settings.
- Clinical investigation for DVT imaging is not supported; alternative applications for this P-selectin tracer should be explored.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
